Ascendis Pharma A/S (A1SN34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 19 Oct 2026
Key indicators
| Last close | BRL 76.48 |
|---|---|
| 52-week range | 70.00 – 94.05 |
| Return, 1 month / 3 months | −17.1% / −17.0% |
| Return, 1 year / 3 years | +1.0% / – |
| Trend | Below its 200-day average |
| RSI (14) | 29 |
| Volatility (1 year) | 29.9% |
| Worst drawdown (1 year) | -19.5% |
| Average daily value traded | 0.00M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ascendis Pharma is a biopharmaceutical company based in Copenhagen, Denmark, that develops long-acting medicines by attaching a drug to a carrier molecule so it releases slowly in the body. Its products treat hormone-related conditions, including growth hormone deficiency in children and low parathyroid hormone in adults. The company serves patients and healthcare providers through specialty medicine markets, and it also runs a commercial operation alongside its research and development work.
Ascendis Pharma A/S is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code A1SN34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ascendis Pharma A/S (A1SN34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 76.48 on 19 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 738 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 1.0% and over the last three months it fell 17.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -5.0% | ||
| From 52-week high | -18.7% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -17.1% | ||
| 6-month return | 0.6% | ||
| 12-month return, skipping the last month | 21.8% | ||
| Stability (higher is calmer) | 77 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.5% | ||
| Liquidity | 20 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M BRL | ||
| Zero-volume days | 71.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +1.0% |
|---|---|
| 1 month | −17.1% |
| 3 months | −17.0% |
| 6 months | +0.6% |
| 1 year | +1.0% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 83.90 / 80.51 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.56 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.